WHO Group 1 pulmonary arterial hypertension: current and investigative therapies. Progress in cardiovascular diseases. 2012;55(2):89-103.Ventetuolo CE,Klinger JR.WHO Group 1pulmonary arterialhypertension:current and investigative therapies.Progress in Cardiovascular Diseases. 2012...
Major advances have been made in the treatment of World Health Organization Group 1 pulmonary arterial hypertension (PAH). Since the mid-1990s, nine medications have become available in the United States to target three key pathophysiologic derangements in PAH – the prostacyclin, endothelin, and nit...
肺动脉高压(Pulmonary Hypertension, PH)是一种罕见但严重的疾病,严重影响了患者的生活质量和预期寿命。根据世界卫生组织(WHO)的分类,PH分为五类,其中WHO 2类肺动脉高压又称为与左心疾病相关的PH,是最常见的亚型之一。本文将重点讨论WHO 2类肺动脉高压的定义、病因、临床表现、诊断和治疗方法。 定义:WHO 2类肺动...
Pulmonary arterial hypertension (PAH) in children refers to increased pressure in the arteries that carry blood from the heart to the lungs. This condition can be classified using the World Health Organization (WHO) functionalclassification system. The WHO classification system is based on the impact...
Pulmonary hypertension is a condition in which there is high blood pressure within the arteries of the lungs, as well as the artery that leads from the heart to the lungs (the pulmonary artery). Symptoms of pulmonary hypertension include fatigue, shortness of breath, pain in the chest, edema...
WINREVAIR is FDA-approved for the treatment of adults with pulmonary arterial hypertension (PAH, WHO Group 1) to increase exercise capacity, improve WHO functional class (FC) and reduce the risk of clinical worsening events. WINREVAIR is the first...
Many clinical trials have been conducted for Group I PH, but the purpose of this study is to evaluate subjects with WHO Group III PH, which includes pulmonary hypertension associated with lung disease and/or hypoxia, as seen in chronic obstructive pulmonary disease (COPD), interstitial lung ...
Prognostic factors in severe pulmonary hypertension patients who need parenteral prostanoid therapy: the impact of late referral. J Heart Lung Transplant 2012; 31: 364-372.Badagliacca R, Pezzuto B, Poscia R, et al. Prognostic factors in severe pulmonary hypertension patients who need parenteral ...
This held true across all circulatory diseases considered (i.e., hypertension, ischemic heart disease, heart failure, hospitalized stroke). Respiratory disease such as chronic obstructive pulmonary disorder (COPD) and diabetes were also more prevalent in the stimulant group compared to the other two ...
Pulmonary hypertension is also a recognised complication of ESKD with the prevalence of the group 5 or “unexplained” type estimated to be 30%-50%.23 The role of pulmonary hypertension in dyspnoea, fatigue, and reduced VO2peak has been demonstrated by several studies in non-ESKD populations ...